Adverum Biotechnologies, Inc. (ADVM)
NASDAQ: ADVM · Real-Time Price · USD
2.210
-0.060 (-2.64%)
At close: May 28, 2025, 4:00 PM
2.202
-0.008 (-0.38%)
After-hours: May 28, 2025, 7:51 PM EDT
Adverum Biotechnologies Stock Forecast
ADVM's stock price has decreased by -70.92% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Adverum Biotechnologies stock ranges from a low of $4.00 to a high of $40. The average analyst price target of $26.4 forecasts a 1,094.57% increase in the stock price over the next year.
Price Target: $26.40 (+1,094.57%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Adverum Biotechnologies stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Maintains $5 → $4 | Hold | Maintains | $5 → $4 | +81.00% | May 15, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $33 | Strong Buy | Maintains | $33 | +1,393.21% | May 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +1,257.47% | May 15, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $40 → $33 | Strong Buy | Maintains | $40 → $33 | +1,393.21% | Apr 17, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $10 → $5 | Hold | Maintains | $10 → $5 | +126.24% | Apr 16, 2025 |
Financial Forecast
Revenue This Year
161.50K
from 1.00M
Decreased by -83.85%
Revenue Next Year
230.27K
from 161.50K
Increased by 42.58%
EPS This Year
-5.51
from -6.62
EPS Next Year
-3.58
from -5.51
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 997,500 | 948,150 | 899,850 | ||
| Avg | 161,497 | 230,265 | 291,383 | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.3% | 487.1% | 290.8% | ||
| Avg | -83.9% | 42.6% | 26.5% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.55 | -2.15 | -2.91 | ||
| Avg | -5.51 | -3.58 | -4.43 | ||
| Low | -6.86 | -6.03 | -5.93 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.